Specifically, even though the T+MTL&Neo group exhibited the highest concentration and rate of change in pTau217, the faster accumulation and higher levels of pTau217 in both the T+MTL and T+Neo groups (relative to the T− group) before the tau scan, combined with the highly replicable well‐known strong association of pTau217 with A+ status,18 indicate that many in these smaller T+ groups are at higher likelihood of transitioning to more advanced biomarker stages of AD in the future. Here, MAPT is linked to Alzheimer disease.